Do analysts rate TCRX or TPST?

TScan Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 552.17%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer ANVS or TPST?

Annovis Bio presently has a consensus price target of $11.67, suggesting a potential upside of 546.35%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Annovis Bio is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, ANVS or TPST?

Annovis Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is ANVS or TPST more profitable?

Annovis Bio's return on equity of -318.08% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Tempest Therapeutics N/A -355.61% -121.21%

Does the media refer more to ANVS or TPST?

In the previous week, Annovis Bio had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for Annovis Bio and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.29 beat Annovis Bio's score of 1.04 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EDSA or TPST?

Edesa Biotech currently has a consensus price target of $5.00, indicating a potential downside of 27.22%. Given Edesa Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Edesa Biotech is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, EDSA or TPST?

Edesa Biotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.34 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is EDSA or TPST more profitable?

Edesa Biotech's return on equity of -286.52% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% Tempest Therapeutics N/A -355.61% -121.21%

Do analysts rate TPST or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer TPST or SCLX?

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 3 articles in the media. Tempest Therapeutics' average media sentiment score of 1.29 beat Scilex's score of 0.83 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TPST or PMVP?

PMV Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 185.71%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable valuation & earnings, TPST or PMVP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is TPST or PMVP more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% PMV Pharmaceuticals N/A -68.98% -62.70%

Tempest Therapeutics (TPST) Competitors

$1.07 +0.09 (+9.13%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$1.04 -0.03 (-2.80%)

As of 07/15/2026 07:51 PM Eastern

Compare

TPST vs. TCRX, ANVS, EDSA, SCLX, and PMVP

Should you buy Tempest Therapeutics stock or one of its competitors? MarketBeat compares Tempest Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tempest Therapeutics include TScan Therapeutics (TCRX), Annovis Bio (ANVS), Edesa Biotech (EDSA), Scilex (SCLX), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry.

How does Tempest Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

TScan Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, suggesting that its share price is 273% less volatile than the broader market.

Tempest Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Tempest Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	5.83	-$129.77M	-$0.96	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

TScan Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 552.17%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tempest Therapeutics had 2 more articles in the media than TScan Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.89 beat Tempest Therapeutics' score of 1.29 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Tempest Therapeutics	Positive

Summary

TScan Therapeutics beats Tempest Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tempest Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

In the previous week, Annovis Bio had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for Annovis Bio and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.29 beat Annovis Bio's score of 1.04 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 36.3% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Annovis Bio's return on equity of -318.08% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Annovis Bio has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, meaning that its share price is 273% less volatile than the broader market.

Annovis Bio presently has a consensus price target of $11.67, suggesting a potential upside of 546.35%. Given Annovis Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Annovis Bio is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Annovis Bio beats Tempest Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tempest Therapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Edesa Biotech currently has a consensus price target of $5.00, indicating a potential downside of 27.22%. Given Edesa Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Edesa Biotech is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Edesa Biotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Edesa Biotech has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, suggesting that its stock price is 273% less volatile than the broader market.

Edesa Biotech's return on equity of -286.52% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
Tempest Therapeutics	N/A	-355.61%	-121.21%

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Tempest Therapeutics' score of 1.29 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
Tempest Therapeutics	Positive

Summary

Edesa Biotech beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Tempest Therapeutics compare to Scilex?

Tempest Therapeutics (NASDAQ:TPST) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tempest Therapeutics has a beta of -1.73, suggesting that its share price is 273% less volatile than the broader market. Comparatively, Scilex has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Tempest Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Scilex	-1,110.17%	N/A	-143.55%

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 3 articles in the media. Tempest Therapeutics' average media sentiment score of 1.29 beat Scilex's score of 0.83 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tempest Therapeutics has higher earnings, but lower revenue than Scilex. Scilex is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Scilex	$30.25M	2.59	-$358.73M	-$40.47	N/A

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tempest Therapeutics beats Scilex on 8 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to PMV Pharmaceuticals?

Tempest Therapeutics (NASDAQ:TPST) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Tempest Therapeutics has a beta of -1.73, indicating that its share price is 273% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

PMV Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 185.71%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PMV Pharmaceuticals' return on equity of -68.98% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

In the previous week, Tempest Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for PMV Pharmaceuticals. Tempest Therapeutics' average media sentiment score of 1.29 beat PMV Pharmaceuticals' score of 0.72 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
PMV Pharmaceuticals	Positive

Summary

PMV Pharmaceuticals beats Tempest Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.67M	$3.01B	$6.78B	$12.56B
Dividend Yield	N/A	2.08%	2.68%	9.45%
P/E Ratio	-0.18	19.41	27.08	24.35
Price / Sales	N/A	354.71	487.23	76.01
Price / Cash	N/A	56.68	48.63	60.00
Price / Book	0.79	4.26	10.82	6.31
Net Income	-$26.26M	$65.13M	$3.59B	$331.55M
7 Day Performance	9.77%	-2.62%	-1.80%	-0.71%
1 Month Performance	-14.40%	3.29%	3.71%	0.16%
1 Year Performance	-83.96%	20.83%	27.41%	19.66%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	1.5185 of 5 stars	$1.07 +9.1%	N/A	-84.0%	$15.67M	N/A	N/A	20	News Coverage Positive News Analyst Forecast
TCRX TScan Therapeutics	4.2713 of 5 stars	$1.05 -0.9%	$6.00 +471.4%	-48.0%	$69.27M	$10.32M	N/A	100	Positive News
ANVS Annovis Bio	3.6567 of 5 stars	$1.98 +2.3%	$13.50 +583.5%	-33.0%	$66.87M	N/A	N/A	3	Gap Up
EDSA Edesa Biotech	1.6052 of 5 stars	$7.21 -3.9%	$5.00 -30.7%	+215.1%	$66.69M	N/A	N/A	20	Positive News
SCLX Scilex	0.8447 of 5 stars	$8.07 +3.3%	N/A	+37.0%	$66.32M	$30.25M	N/A	80	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. TCRX, ANVS, EDSA, SCLX, and PMVP

How does Tempest Therapeutics compare to TScan Therapeutics?

Summary

How does Tempest Therapeutics compare to Annovis Bio?

Summary

How does Tempest Therapeutics compare to Edesa Biotech?

Summary

How does Tempest Therapeutics compare to Scilex?

Summary

How does Tempest Therapeutics compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. TCRX, ANVS, EDSA, SCLX, and PMVP

How does Tempest Therapeutics compare to TScan Therapeutics?

Which has more volatility and risk, TCRX or TPST?

Is TCRX or TPST more profitable?

Which has preferable earnings & valuation, TCRX or TPST?

Do analysts rate TCRX or TPST?

Do insiders & institutionals have more ownership in TCRX or TPST?

Does the media refer more to TCRX or TPST?

Summary

How does Tempest Therapeutics compare to Annovis Bio?

Does the media refer more to ANVS or TPST?

Which has better earnings and valuation, ANVS or TPST?

Do insiders & institutionals hold more shares of ANVS or TPST?

Is ANVS or TPST more profitable?

Which has more risk & volatility, ANVS or TPST?

Do analysts prefer ANVS or TPST?

Summary

How does Tempest Therapeutics compare to Edesa Biotech?

Do analysts recommend EDSA or TPST?

Which has stronger earnings and valuation, EDSA or TPST?

Which has more volatility and risk, EDSA or TPST?

Is EDSA or TPST more profitable?

Do institutionals and insiders have more ownership in EDSA or TPST?

Does the media refer more to EDSA or TPST?

Summary

How does Tempest Therapeutics compare to Scilex?

Do analysts rate TPST or SCLX?

Which has more volatility and risk, TPST or SCLX?

Is TPST or SCLX more profitable?

Does the media prefer TPST or SCLX?

Which has higher valuation & earnings, TPST or SCLX?

Do institutionals & insiders have more ownership in TPST or SCLX?

Summary

How does Tempest Therapeutics compare to PMV Pharmaceuticals?

Which has preferable valuation & earnings, TPST or PMVP?

Which has more volatility & risk, TPST or PMVP?

Do analysts prefer TPST or PMVP?

Do institutionals and insiders believe in TPST or PMVP?

Is TPST or PMVP more profitable?

Does the media refer more to TPST or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools